Publications by authors named "B van Benthem"
Introduction: Oral pre-exposure prophylaxis (PrEP) prevents Human Immunodeficiency Virus (HIV) acquisition. In the Netherlands, PrEP is accessible through the national PrEP program (NPP) or general practitioners (GP). Still, some men who have sex with men (MSM) entering HIV care indicated having PrEP experience prior to diagnosis.
View Article and Find Full Text PDFArticle Synopsis
- * A study involving 4,488 young women assessed the vaccine's effectiveness against specific HPV types, finding high efficacy rates of 93.5% for HPV-16 and 89.5% for HPV-18, with additional cross-protection against other types.
- * Results showed that the vaccine's effectiveness was similar for women who participated in catch-up vaccinations compared to those who received routine vaccinations, indicating both approaches are equally effective.
Article Synopsis
- In the Netherlands, since the introduction of HIV pre-exposure prophylaxis (PrEP) in 2019, about 16% of new HIV diagnoses among men who have sex with men (MSM) and transgender persons (TGP) reported prior PrEP use.
- Many individuals who did not use PrEP cited reasons like low risk perception and lack of access, highlighting barriers to its uptake.
- The study identified an increase in PrEP-associated mutations linked to resistance in new infections since 2019, but found no evidence of these mutations being transmitted to others.
Article Synopsis
- From 2009 to 2021, the Netherlands only offered bivalent HPV vaccination to girls, prompting an investigation into its effects on genital HPV prevalence among young adults.
- Data were collected through a study called PASSYON, which involved sexual health clinic clients aged 16-24, revealing significant declines in certain high-risk HPV types amongst vaccinated and unvaccinated females over time.
- The study highlighted successful herd protection effects of the vaccination for heterosexual males and unvaccinated females, while also indicating concerning trends of increasing HPV types related to vaccine phylogeny, suggesting potential type-replacement issues.